Dutch biotechnology company Crucell has secured funding from the U.S. Agency for International Development to speed up the development of malaria vaccines, Reuters reports. The funding will allow Crucell and the PATH Malaria Vaccine Initiative to conduct researches on the effectiveness of Crucell's malaria vaccines. The Dutch firm did not reveal any financial specifics.
Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).
About the author
Ma. Rizza Leonzon
As a former staff writer, Rizza focused mainly on business coverage, including key donors such as the Asian Development Bank and AusAID.
